enasidenib has been researched along with Leukemia--Myeloid--Acute* in 1 studies
1 other study(ies) available for enasidenib and Leukemia--Myeloid--Acute
| Article | Year |
|---|---|
Structure-based design, synthesis and bioactivity evaluation of macrocyclic inhibitors of mutant isocitrate dehydrogenase 2 (IDH2) displaying activity in acute myeloid leukemia cells.
The enzymes involved in the metabolic pathways in cancer cells have been demonstrated as important therapeutic targets such as the isocitrate dehydrogenase 2 (IDH2). A series of macrocyclic derivatives was designed based on the marketed IDH2 inhibitor AG-221 by using the conformational restriction strategy. The resulted compounds showed moderate to good inhibitory potential against different IDH2-mutant enzymes. Amongst, compound C6 exhibited better IDH2 Topics: Antineoplastic Agents; Cell Line, Tumor; Chemistry Techniques, Synthetic; Drug Design; Enzyme Inhibitors; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Macrocyclic Compounds; Molecular Docking Simulation; Mutation; Protein Conformation | 2020 |